STRUCTURED BENEFIT-RISK ASSESSMENT OF TRIPTAN TREATMENTS USING PATIENT-PREFERENCE DATA

被引：1
|
作者：
Gonzalez, J. M. [1 ]
Hauber, A. B. [1 ]
Levitan, B. [2 ]
Coplan, P. [3 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Johnson & Johnson PRD, Titusville, NJ USA
[3] Purdue Pharma LP, Stamford, CT USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.795
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A147 / A147
页数：1
相关论文
共 50 条
  • [1] Structured Approaches to Benefit-Risk Assessment: A Case Study and the Patient Perspective
    Levitan, Bennett
    Phillips, Lawrence D.
    Walker, Stuart
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 564 - 573
  • [2] Structured Approaches to Benefit-Risk Assessment: A Case Study and the Patient Perspective
    Bennett Levitan
    Lawrence D. Phillips
    Stuart Walker
    [J]. Therapeutic Innovation & Regulatory Science, 2014, 48 : 564 - 573
  • [3] A BENEFIT-RISK ASSESSMENT OF DARIDOREXANT FOR THE TREATMENT OF INSOMNIA USING PATIENT PREFERENCE DATA FROM TWO PHASE 3 TRIALS
    Heidenreich, S.
    Phillips-Beyer, A.
    Ross, M.
    Chua, G. Nie
    Fietze, I.
    Mayleben, D.
    [J]. SLEEP MEDICINE, 2022, 100 : S106 - S107
  • [4] A BENEFIT-RISK ASSESSMENT OF DARIDOREXANT FOR THE TREATMENT OF INSOMNIA USING PATIENT PREFERENCE DATA FROM TWO PHASE 3 TRIALS
    Heidenreich, Sebastian
    Phillips-Beyer, Andrea
    Ross, Melissa
    Chua, Gin Nie
    Fietze, Ingo
    Mayleben, David
    [J]. SLEEP, 2021, 44 : A137 - A137
  • [5] Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature
    Kurzinger, Marie-Laure
    Douarin, Ludivine
    Uzun, Ievgeniia
    El-Haddad, Chantal
    Hurst, William
    Juhaeri, Juhaeri
    Tcherny-Lessenot, Stephanie
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
  • [6] Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis
    Sidi, Yulia
    Harel, Ofer
    [J]. VALUE IN HEALTH, 2020, 23 (12) : 1622 - 1629
  • [7] Benefit-risk assessment of treatments for heparin-induced thrombocytopenia
    Messmore, HL
    Jeske, WP
    Wehrmacher, WH
    Walenga, JM
    [J]. DRUG SAFETY, 2003, 26 (09) : 625 - 641
  • [8] Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia
    Harry L. Messmore
    Walter P. Jeske
    William H. Wehrmacher
    Jeanine M. Walenga
    [J]. Drug Safety, 2003, 26 : 625 - 641
  • [9] PATIENT PREFERENCE WEIGHTS FOR BENEFIT-RISK ANALYSIS: A STATIN CASE STUDY
    Johnson, F. R.
    Hauber, A. B.
    Gonzalez, J. M.
    Levitan, B.
    Copland, P.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A19 - A19
  • [10] Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?
    Janine A. van Til
    Maarten J. IJzerman
    [J]. PharmacoEconomics, 2014, 32 : 1 - 4
12345